help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gomez-Sanchez, E. P.
Right arrow Articles by Gomez-Sanchez, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gomez-Sanchez, E. P.
Right arrow Articles by Gomez-Sanchez, C. E.

Endocrinology, Vol 118, 2582-2587, Copyright © 1986 by Endocrine Society


ARTICLES

A reevaluation of the mineralocorticoid and hypertensinogenic potential of 19-hydroxyandrostenedione

EP Gomez-Sanchez and CE Gomez-Sanchez

Experiments were done to evaluate whether 19-hydroxyandrostenedione (19- OH-A) is a steroid which produces hypertension and amplifies the mineralocorticoid effects of aldosterone. No intrinsic mineralocorticoid or adosterone-amplifying effect was found in several bioassays using adrenalectomized rats at doses of 100 micrograms 19-OH- A and/or 0.1 microgram aldosterone or in assays in which urine electrolytes were measured daily during a 14-day continuous infusion of 100 micrograms/day 19-OH-A. In two different experiments, the twice weekly administration of 0.1-1 mg 19-OH-A in oil to intact rats' drinking water failed to produce a change in blood pressure after 6 weeks. When one kidney was removed from these rats and 0.9% saline was substituted for drinking water, the blood pressures of rats receiving 1 mg twice weekly of 19-OH-A became significantly elevated in only one of the two experiments. At the end of 10 weeks, the average 19-OH-A pressure (139 mmHg) was significantly (P less than 0.01) greater than average control pressure (114 mmHg), but significantly (P less than 0.01) less than the mean average pressure of rats receiving 5 mg deoxycorticosterone acetate (DOCA) (161 mmHg). In another experiment uninephrectomized rats received 0.5 mg 19-OH-A or 1 mg DOCA 3 times a week. After 5 weeks the pressure of those receiving 19-OH-A was 149 mmHg, significantly greater (P less than 0.01) than controls (123 mmHg), but significantly less (P less than 0.01) than that of those rats receiving DOCA (189 mmHg). Our data failed to confirm the aldosterone amplifying effect of 19-OH-A. We did obtain a small elevation of arterial pressure in unilaterally nephrectomized rats receiving saline to drink. The differences between our results and those reported for this compound are not readily apparent, but may be related to genetic differences within the Sprague-Dawley strain used in both studies and/or to diet.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society